{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T16:40:38Z","timestamp":1787503238073,"version":"build-2736575974"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","internationaljournalofcardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.ijcard.2022.05.052","type":"journal-article","created":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T23:45:47Z","timestamp":1653522347000},"page":"153-157","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Novel multiple sclerosis agents-associated cardiotoxicity: A real-world pharmacovigilance study"],"prefix":"10.1016","volume":"362","author":[{"given":"Zaki","family":"Al-Yafeai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Carvajal-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamzah","family":"Abduljabar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammed","family":"Arvas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaan","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neev","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ijcard.2022.05.052_bb0005","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/s41572-018-0041-4","article-title":"Multiple sclerosis","volume":"4","author":"Filippi","year":"2018","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"9","key":"10.1016\/j.ijcard.2022.05.052_bb0010","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/nri3871","article-title":"Immunopathology of multiple sclerosis","volume":"15","author":"Dendrou","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ijcard.2022.05.052_bb0015","series-title":"Sphingosine 1-Phosphate: Lipid Signaling in Pathology and Therapy","volume":"366(6463)","author":"Cartier","year":"2019"},{"key":"10.1016\/j.ijcard.2022.05.052_bb0020","series-title":"Sphingosine 1-Phosphate Receptor Modulator Therapy for Multiple Sclerosis: Differential Downstream Receptor Signalling and Clinical Profile Effects","first-page":"207","volume":"81(2)","author":"Chun","year":"2021"},{"issue":"2","key":"10.1016\/j.ijcard.2022.05.052_bb0025","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.clim.2014.09.012","article-title":"Safety, efficacy, and pharmacokinetics\/pharmacodynamics of daclizumab (anti-CD25) in patients with adult T-cell leukemia\/lymphoma","volume":"155","author":"Berkowitz","year":"2014","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.ijcard.2022.05.052_bb0030","series-title":"B cells in Multiple Sclerosis - from Targeted Depletion to Immune Reconstitution Therapies","first-page":"399","volume":"17(7)","author":"Cencioni","year":"2021"},{"key":"10.1016\/j.ijcard.2022.05.052_bb0035","doi-asserted-by":"crossref","first-page":"760","DOI":"10.3389\/fimmu.2020.00760","article-title":"B and T cells driving multiple sclerosis: identity, mechanisms and potential triggers","volume":"11","author":"van Langelaar","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ijcard.2022.05.052_bb0040","series-title":"Anti-CD20 Agents for Multiple Sclerosis: Spotlight on Ocrelizumab and Ofatumumab","volume":"10(10)","author":"Florou","year":"2020"},{"issue":"3","key":"10.1016\/j.ijcard.2022.05.052_bb0045","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.ijcard.2022.05.052_bb0050","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1606468","article-title":"Ocrelizumab versus placebo in primary progressive multiple sclerosis","volume":"376","author":"Montalban","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.ijcard.2022.05.052_bb0055","doi-asserted-by":"crossref","first-page":"18","DOI":"10.15171\/jrip.2017.04","article-title":"Non-ischemic cardiomyopathy after rituximab treatment for membranous nephropathy","volume":"6","author":"Cheungpasitporn","year":"2017","journal-title":"J. Renal. Inj Prev."},{"issue":"20","key":"10.1016\/j.ijcard.2022.05.052_bb0060","doi-asserted-by":"crossref","first-page":"e1805","DOI":"10.1212\/WNL.0000000000005516","article-title":"Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: the MIRROR study","volume":"90","author":"Bar-Or","year":"2018","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.ijcard.2022.05.052_bb0065","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1177\/1352458508097468","article-title":"Daclizumab in treatment of multiple sclerosis patients","volume":"15","author":"Ali","year":"2009","journal-title":"Mult. Scler."},{"issue":"4","key":"10.1016\/j.ijcard.2022.05.052_bb0070","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.ijcard.2022.05.052_bb0075","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/ajh.20303","article-title":"Ventricular tachycardia associated with infusion of rituximab in mantle cell lymphoma","volume":"78","author":"Arai","year":"2005","journal-title":"Am. J. Hematol."},{"issue":"9805","key":"10.1016\/j.ijcard.2022.05.052_bb0080","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/S0140-6736(11)61649-8","article-title":"Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial","volume":"378","author":"Kappos","year":"2011","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ijcard.2022.05.052_bb0085","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/art.33317","article-title":"Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a forty-eight-week randomized, double-blind, placebo-controlled, parallel-group phase III trial","volume":"64","author":"Rigby","year":"2012","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.ijcard.2022.05.052_bb0090","first-page":"31","article-title":"Treating primary-progressive multiple sclerosis: potential of ocrelizumab and review of B-cell therapies","volume":"7","author":"Feng","year":"2017","journal-title":"Degener. Neurol. Neuromuscul. Dis."},{"issue":"3","key":"10.1016\/j.ijcard.2022.05.052_bb0095","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1400376","article-title":"Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia","volume":"371","author":"Byrd","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.ijcard.2022.05.052_bb0100","article-title":"Cardiotoxicity of novel targeted hematological therapies","volume":"10","author":"Giudice","year":"2020","journal-title":"Life (Basel)"},{"issue":"5","key":"10.1016\/j.ijcard.2022.05.052_bb0105","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1056\/NEJMoa0907839","article-title":"Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis","volume":"362","author":"Cohen","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.ijcard.2022.05.052_bb0110","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1056\/NEJMoa0909494","article-title":"A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis","volume":"362","author":"Kappos","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.ijcard.2022.05.052_bb0115","first-page":"119","article-title":"Cardiovascular effects of fingolimod: a review article","volume":"13","author":"Behjati","year":"2014","journal-title":"Iran J. Neurol."}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016752732200763X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016752732200763X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T20:57:12Z","timestamp":1759093032000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016752732200763X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":23,"alternative-id":["S016752732200763X"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2022.05.052","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.12.11.21267656","asserted-by":"object"},{"id-type":"doi","id":"10.22541\/au.164873539.99715621\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.22541\/au.164873539.99715621\/v2","asserted-by":"object"}]},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel multiple sclerosis agents-associated cardiotoxicity: A real-world pharmacovigilance study","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2022.05.052","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}